iSpecimen Inc. Announces Pricing of Approximately $1.75 Million Private Placement Priced At-the-Market
iSpecimen (Nasdaq: ISPC), an online marketplace for biospecimens, has announced a $1.75 million private placement of securities priced at-the-market. The company will issue 1,559,828 shares of common stock (or pre-funded warrants) at $1.122 per share.
The offering, expected to close around August 1, 2025, will be placed through WestPark Capital, Inc. Of the proceeds, $500,000 will be allocated to marketing services through IR Agency LLC, with the remainder used for working capital and general corporate purposes. The securities are being offered exclusively to accredited investors and will require registration with the SEC for resale.
iSpecimen (Nasdaq: ISPC), un marketplace online per biospecimen, ha annunciato un collocamento privato di titoli per 1,75 milioni di dollari a prezzo di mercato. La società emetterà 1.559.828 azioni ordinarie (o warrant pre-finanziati) al prezzo di 1,122 dollari per azione.
L'offerta, che si prevede si concluda intorno al 1° agosto 2025, sarà collocata tramite WestPark Capital, Inc. Dei proventi, 500.000 dollari saranno destinati a servizi di marketing tramite IR Agency LLC, mentre il resto sarà utilizzato per il capitale circolante e scopi aziendali generali. I titoli sono offerti esclusivamente a investitori accreditati e richiederanno la registrazione presso la SEC per la rivendita.
iSpecimen (Nasdaq: ISPC), un mercado en línea de biospecímenes, ha anunciado una colocación privada de valores por 1.75 millones de dólares a precio de mercado. La compañía emitirá 1,559,828 acciones comunes (o garantías prefinanciadas) a 1.122 dólares por acción.
La oferta, que se espera cerrar alrededor del 1 de agosto de 2025, será colocada a través de WestPark Capital, Inc. De los ingresos, 500,000 dólares se destinarán a servicios de marketing a través de IR Agency LLC, y el resto se utilizará para capital de trabajo y propósitos corporativos generales. Los valores se ofrecen exclusivamente a inversores acreditados y requerirán registro ante la SEC para su reventa.
iSpecimen (나스닥: ISPC)는 바이오샘플 온라인 마켓플레이스이며, 시장 가격으로 175만 달러 규모의 사모 발행을 발표했습니다. 회사는 1,559,828주의 보통주(또는 선지급 워런트)를 주당 1.122달러에 발행할 예정입니다.
이번 공모는 2025년 8월 1일경 마감될 예정이며 WestPark Capital, Inc.를 통해 배정됩니다. 수익금 중 50만 달러는 IR Agency LLC를 통한 마케팅 서비스에 할당되며, 나머지는 운전자본 및 일반 법인 목적에 사용됩니다. 증권은 공인 투자자에게만 제공되며, 재판매를 위해 SEC 등록이 필요합니다.
iSpecimen (Nasdaq : ISPC), une place de marché en ligne pour les biospécimens, a annoncé un placement privé de titres d'une valeur de 1,75 million de dollars au prix du marché. La société émettra 1 559 828 actions ordinaires (ou des bons de souscription préfinancés) au prix de 1,122 dollar par action.
L'offre, qui devrait se clôturer aux alentours du 1er août 2025, sera placée par WestPark Capital, Inc. Sur les fonds récoltés, 500 000 dollars seront alloués à des services marketing via IR Agency LLC, le reste étant destiné au fonds de roulement et aux besoins généraux de l'entreprise. Les titres sont offerts exclusivement aux investisseurs accrédités et nécessiteront une inscription auprès de la SEC pour la revente.
iSpecimen (Nasdaq: ISPC), ein Online-Marktplatz für Biospezimen, hat eine Private Placement von Wertpapieren im Wert von 1,75 Millionen US-Dollar zum Marktpreis angekündigt. Das Unternehmen wird 1.559.828 Stammaktien (oder vorfinanzierte Warrants) zu 1,122 US-Dollar pro Aktie ausgeben.
Das Angebot, das voraussichtlich um den 1. August 2025 abgeschlossen wird, wird über WestPark Capital, Inc. platziert. Von den Erlösen werden 500.000 US-Dollar für Marketingdienstleistungen über IR Agency LLC verwendet, der Rest dient dem Betriebskapital und allgemeinen Unternehmenszwecken. Die Wertpapiere werden ausschließlich an akkreditierte Investoren angeboten und erfordern für den Weiterverkauf eine Registrierung bei der SEC.
- Raises $1.75 million in new capital to strengthen working capital position
- Securities priced at-the-market under Nasdaq rules, indicating fair market value
- Potential dilution for existing shareholders with issuance of 1,559,828 new shares
- Significant portion ($500,000) of proceeds allocated to marketing rather than core operations
Insights
iSpecimen raises $1.75M in private placement at $1.122 per share, allocating $500K to marketing with the remainder for working capital.
iSpecimen's $1.75 million private placement represents a strategic capital raise for this biospecimen marketplace. The company is issuing 1,559,828 shares (or pre-funded warrants) at $1.122 per share, which is priced at-the-market under Nasdaq rules - meaning the offering is priced at or near the current trading price rather than at a significant discount.
The capital allocation strategy reveals immediate priorities: $500,000 (approximately 28.6% of gross proceeds) earmarked specifically for marketing and advertising services through IR Agency LLC, with the remainder designated for working capital and general corporate purposes. This suggests management is focused on increasing market visibility and maintaining operational liquidity.
This private placement to accredited investors (sophisticated investors meeting specific income or net worth thresholds) circumvents the more rigorous public offering process. The company has committed to filing registration statements with the SEC to allow these investors to eventually resell their shares, providing them with a path to liquidity.
For a smaller publicly-traded company like iSpecimen, which operates a specialized marketplace connecting biospecimen providers with researchers, this capital injection represents meaningful financial support without the dilutive impact of a larger offering. The use of WestPark Capital as placement agent indicates a structured approach to raising this capital efficiently through institutional channels.
WOBURN, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it entered into a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately
In connection with the offering, the Company will issue 1,559,828 shares of common stock (or pre-funded warrants to purchase shares of common stock) at a purchase price of
The offering is expected to close on or about August 1, 2025, subject to the satisfaction of customary closing conditions.
WestPark Capital, Inc. is acting as the exclusive placement agent in connection with the offering.
Additional details regarding the offering will be available in a Form 8-K to be filed by the Company with the Securities and Exchange Commission (the "SEC").
The securities described above have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investor, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock and the shares issuable upon exercise of the pre-funded warrants.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning the development of our company. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The reader is cautioned not to rely on such forward-looking statements. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including the uncertainty regarding future commercial success; risks and uncertainties associated with market conditions and the Company’s ability to satisfy the closing conditions related to the Offering. These and other factors may cause our actual results to differ materially from any forward-looking statements. Forward-looking statements are only predictions and actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 14, 2025, as well as other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iSpecimen specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
FAQ
What is the size and price of iSpecimen's (ISPC) private placement announced on July 31, 2025?
How will iSpecimen (ISPC) use the proceeds from the private placement?
When is iSpecimen's (ISPC) private placement expected to close?
Who is eligible to participate in iSpecimen's (ISPC) private placement?
What does iSpecimen (ISPC) do as a company?
